Key Highlights
- Anette Engelhardt joins Bio-Rad as EVP and President of Clinical Diagnostics Group.
- Effective June 10, 2024, she will lead the clinical diagnostics strategy.
- Extensive experience from Cepheid and bioMerieux enhances Bio-Rad’s leadership team.
- Strong track record in developing and commercializing novel diagnostics products.
Source: Business Wire
Notable Quote
- “Anette brings to Bio-Rad extensive operational experience and a successful track record in developing and commercializing novel diagnostics products across multiple markets. We are confident her expertise will help advance our clinical diagnostics strategy to extend Bio-Rad’s core diagnostics and develop new products and market entries for our clinical business.” – Andy Last, Executive Vice President and Chief Operating Officer at Bio-Rad
SoHC's Take
The appointment of Anette Engelhardt as Executive Vice President and President of Bio-Rad’s Clinical Diagnostics Group marks a significant strategic move for the company. With her extensive background in molecular diagnostics and in vitro technologies, Engelhardt is well-positioned to drive innovation and expansion within Bio-Rad’s clinical diagnostics segment. Her leadership experience at Cepheid and bioMerieux, combined with her proven ability to commercialize cutting-edge products, will be invaluable as Bio-Rad seeks to strengthen its market presence and advance its portfolio of diagnostic solutions. This appointment underscores Bio-Rad’s commitment to excellence and innovation in the life sciences sector, setting the stage for continued growth and success.
